Exclusive Summary

• The originator (PegIntron) has lost patent exclusivity and been discontinued in many markets, leaving a massive structural supply vacuum that generic alternatives can easily capitalize on for HBV/HDV treatments.
• With over 254 million chronic HBV and 15 million HDV patients globally, the drug remains firmly established on the WHO Essential Medicines List (EML) and as a guideline-recommended first-line therapy.
• Tremendously high technical barriers in pegylation limit generic competition worldwide, while the 180mcg Pre-Filled Syringe (PFS) formulation offers excellent patient compliance and devastating commercial cost-effectiveness, ideal for distributors and institutional tenders in emerging markets.